anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An immune-peroxidase test for serologic diagnostics of porcine reproductive and respiratory syndrome virus includes inoculation of cells of sensitive culture to 96-well plastic microplates with flat bottom; dilution of test serums by the method of two-fold dilution with addition of working dilution of reproductive and respiratory syndrome virus in the 96-well plastic microplates with round bottom with following contact of those and with bringing to the holes of the microplate with mono-layer of cell culture; incubation during seven days under conditions of COincubator; removal from the microplate wells of the culture medium, with washing the cell mono-layer; introduction of fixing buffer to all the microplate wells; step-by-step introduction to all the microplate wells – working dilution of specific blood serum, working dilution of conjugate, solution of substrate; termination of reaction through adding stop-solution to each well of the table and registration of reaction under inverted light microscope based on the principle of presence or absence of specific dyeing of the cells – infected cells look like single cells or groups of cells (plaques) with cytoplasm dyed to dark-red color and light nucleus. For reveal of specific humoral antibodies against the reproductive and respiratory syndrome virus in domestic and wild hog biological material (serum of blood, milk, colostrums) is determined. For cultivation sensitive to reproductive and respiratory syndrome virus cell cultures (CL 2621, MA-104, MARC-145) are used; grown in cultural vessels (glass or plastic pads). The cell monolayer is taken by means of solution of trypsin-versen at ratio 1:9. For cultivation of cell culture, 7-10 % of embryo blood serum of cattle is added to nutrient media. The test blood serums before investigation undergo inactivation at temperature during 30 minutes with titration with the method of double dilution with adding working dilution 1000 U of reproductive and respiratory syndrome virus (reference - "Lelystad", "Hesse" or deposited strains) with exposition during one hour at +; content is added to the microplate wells with the sensitive culture of cells with pre-grown (48-72 hours) mono-layer with addition of 2 % embryo serum of cattle blood. As control virus the reference or deposited strains of reproductive and respiratory syndrome virus are used. At fixation of mono-layer of cells 96 % ethyl alcohol is used. Porcine specific blood serum against the reproductive and respiratory syndrome virus is used as working dilution of positive serum. Tvin-20 is not used when monolayer is washed. At termination of reaction – NaCL; all manipulations with drying the cell mono-layer are carried out under conditions of thermostat at temperature and exposition – one hour. While recording of the reaction the presence of plaque – absence of antibodies, and the absence of plaque – presence of anti-bodies against the reproductive and respiratory syndrome virus in porcine blood serums are taken into account.
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.
Atazanavir has been shown to prolong the PR interval of the electrocardiogram in some patients. In healthy volunteers and in patients, abnormalities in atrioventricular (AV) conduction were asymptomatic and generally limited to first-degree AV block. There have been reports of second-degree AV block and other conduction abnormalities [see Adverse Reactions (6.4) and Overdosage (10)]. In clinical trials that included electrocardiograms, asymptomatic first-degree AV block was observed in 5.9% of atazanavir-treated patients (n=920), 5.2% of lopinavir/ritonavir-treated patients (n=252), 10.4% of nelfinavir-treated patients (n=48), and 3.0% of efavirenz-treated patients (n=329). In Study AI424-045, asymptomatic first-degree AV block was observed in 5% (6/118) of atazanavir/ritonavir-treated patients and 5% (6/116) of lopinavir/ritonavir-treated patients who had on-study electrocardiogram measurements. Because of limited clinical experience in patients with preexisting conduction system disease (eg, marked first-degree AV block or second- or third-degree AV block), atazanavir should be used with caution in these patients. [See Clinical Pharmacology (12.2).]

Atazanavir in combination with diltiazem increased diltiazem plasma concentration by 2-fold with an additive effect on the PR interval. When used in combination with atazanavir, a dose reduction of diltiazem by one-half should be considered and ECG monitoring is recommended. In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, no clinically significant additive effect of atazanavir and atenolol on the PR interval was observed. Dose adjustment of atenolol is not required when used in combination with atazanavir. [See Drug Interactions (7) and Clinical Pharmacology (12.2).] Pharmacokinetic studies between atazanavir and other drugs that prolong the PR interval including beta blockers [other than atenolol, see Drug Interactions (7)], verapamil, and digoxin have not been performed. An additive effect of atazanavir and these drugs cannot be excluded; therefore, caution should be exercised when atazanavir is given concurrently with these drugs, especially those that are metabolized by CYP3A (eg, verapamil).
The routine clinical outpatient follow-up protocol was implemented, and a postoperative rehabilitation health manual was provided to patients the day following LEEP surgery. Outpatient evaluations were subsequently conducted at 1 month, 3 months, and 6 months post-surgery.
In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
PURPOSE:To provide a fat emulsion containing a paramagnetic metal atom and useful for a nuclear magnetic resonance diagnosis method used for clinical diagnosis. CONSTITUTION:The contrast medium for MRI diagnosis contains a compound of the formula (m is 1-3; R1, R2 are H, lower alkyl; R3 to R6 are OH, etc.,) capable of forming a chelate bond with a paramagnetic metal atom (e.g. Gd, Tb, Ho). The preferable composition comprises 0.01-15% of the paramagnetic metal atom, the compound of the formula in a molar rate of approximately 1-5 based on the paramagnetic metal atom, 0.5-50%W/V of a fat or oil (e.g. soybean oil), an emulsifier (e.g. phospholipid, synthetic surfactant) in an amount of 1-100 pts.wt. per 100 pts.wt. of the fat or oil, and a suitable amount of water. When used as a contrast medium for MRI diagnosis, the fat emulsion gives images having excellent contrasts and has an effect to transfer to various organ tissues such as reticuloendothelial system organs, inflammatory sites and arteriosclerotic sites.
<P>PROBLEM TO BE SOLVED: To obtain a composition from a pressurized fluid and a reducing agent and/or an oxidizing agent for treatment of keratin fibers.  <P>SOLUTION: This invention relates to the composition obtained by a process comprising a step in which fluid is percolated under a pressure of at least 3X10<SP>5</SP>Pa (3 bar) through at least one reducing agent, and/or at least one oxidizing agent in solid or pasty form, for the treatment of keratin fibers. The invention relates to the use of the composition for bleaching keratin fibers. The invention also relates to the use of a steam composition for the permanent wave treatment of keratin fibers. A composition capable of changing concentrations of the reducing agent and the oxidizing agent of the composition, if necessary, is obtained in a very short time by percolating the fluid through the reducing agent and/or oxidizing agent, and a problem of the solubility of a preservative is solved without using the preservative.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND: Rare diseases affect approximately 400 million people worldwide. Many of them suffer from delayed diagnosis. Among them, NPHP1-related renal ciliopathies need to be diagnosed as early as possible as potential treatments have been recently investigated with promising results. Our objective was to develop a supervised machine learning pipeline for the detection of NPHP1 ciliopathy patients from a large number of nephrology patients using electronic health records (EHRs).
METHODS AND RESULTS: We designed a pipeline combining a phenotyping module re-using unstructured EHR data, a semantic similarity module to address the phenotype dependence, a feature selection step to deal with high dimensionality, an undersampling step to address the class imbalance, and a classification step with multiple train-test split for the small number of rare cases. The pipeline was applied to thirty NPHP1 patients and 7231 controls and achieved good performances (sensitivity 86% with specificity 90%). A qualitative review of the EHRs of 40 misclassified controls showed that 25% had phenotypes belonging to the ciliopathy spectrum, which demonstrates the ability of our system to detect patients with similar conditions.
CONCLUSIONS: Our pipeline reached very encouraging performance scores for pre-diagnosing ciliopathy patients. The identified patients could then undergo genetic testing. The same data-driven approach can be adapted to other rare diseases facing underdiagnosis challenges.
The pterygomandibular raphe (PMR) is a tendinous bundle between the bucinator (BM) and the superior constrictor of pharynx (SC) and has been considered essential for swallowing. Despite its functional significance, previous studies reported that the PMR is not always present. Another study reported presence of the connecting fascia between the BM and deep temporalis tendon (dTT). Therefore, the present study analyzed the three-dimensional relationship between the BM, SC, and dTT. We examined 13 halves of 11 heads from adult Japanese and Caucasian cadavers: eight halves macroscopically and five halves histologically. There was no clear border between the BM and SC in any specimens macroscopically. The BM attachment varied depending on its levels. At the level of the superior part of the internal oblique line, the BM fused with the SC with no clear border. At the level of the midpart of the internal oblique line of the mandible, the BM attached to the dTT directly, and the SC attached to the dTT via collagen fibers and the BM. Based on these results, these muscles should be described as the BM/dTT/SC (BTS) complex. The three-dimensional relationship of the BTS complex might result in the so-called "pterygomandibular raphe." The BTS complex could be important as a muscle coordination center in chewing and swallowing.
Reports of necrotizing fasciitis of the perineum (Fournier's gangrene), a rare but serious and life-threatening necrotizing infection requiring urgent surgical intervention, have been identified in patients with diabetes mellitus receiving SGLT2 inhibitors, including JARDIANCE. Cases have been reported in both females and males. Serious outcomes have included hospitalization, multiple surgeries, and death. 

Patients treated with JARDIANCE presenting with pain or tenderness, erythema, or swelling in the genital or perineal area, along with fever or malaise, should be assessed for necrotizing fasciitis. If suspected, start treatment immediately with broad-spectrum antibiotics and, if necessary, surgical debridement. Discontinue JARDIANCE, closely monitor blood glucose levels, and provide appropriate alternative therapy for glycemic control.
BACKGROUND: Stenosis and obliteration of the pulmonary vein can be developed by multiple diseases and might cause hemoptysis. Traditional therapy including surgical procedure and conservative treatments might be inappropriate choices to manage massive hemoptysis.
CASE PRESENTATION: A 64-year-old man, diagnosed with advanced stage IVA lung squamous cell carcinoma, presented with dyspnea and recurrent, massive hemoptysis. An initial contrast-enhanced computed tomography revealed a giant tumor in the left lung hilus and occlusion of the left superior pulmonary vein. Despite immediate selective bronchial artery embolization and simultaneous embolization of an anomalous branch of the internal thoracic artery, the massive hemoptysis continued. Subsequently, embolization of the left superior pulmonary artery was performed, achieving functional pulmonary lobectomy, which successfully treated the hemoptysis without relapse during a six-month follow-up. The patient continues to undergo cancer therapy and remains stable.
CONCLUSIONS: This case successfully managed massive hemoptysis associated with lung cancer invasion into the pulmonary vein through functional pulmonary lobectomy via embolization of the corresponding pulmonary artery.
Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
An image capture method is provided. In accordance with the method, an image of the scene is captured and affective information is collected a capture. The scene image and affective information are transmitted to an image receiver. An imaging system is also provided having an image capture system adapted to capture an image of a scene and a memory which stores the captured image. A set of sensors is adapted to collect affective signals from the user at capture. A processor is adapted to determine affective information based upon the affective signals and to associate affective information with the captured image. A transmitter sends the scene image and the affective information to a receiver.
Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
PURPOSE:To preserve a substance containing the titled compound, by sealing a substance containing eicosapentaenoic acid, etc. and a deoxidant in a gas barrier packing material, adding no other substance to it, not processing it, keeping it stably for a long period. CONSTITUTION:A substance such as fish oil that has clearly preventing and remedying effect on myocardial infraction, etc., containing eicosapentaenoic acid and docosapentaenoic acid and a disoxidant having ability to absorb O2 are sealed in a gas barrier packing material such as biaxially oriented nylon coated with polyvinylidene chloride/polyethylene laminate film, etc. and preserved. After the sealing, reduction in content of the compounds can be prevented for >=6 months by keeping it at room temperature, and when the temperature is kept at <=room temperature (e.g., 2--30 deg.C), it can be preserved stably for a longer period. EFFECT:Formation of peroxide lipid, occurrence of molds and insect pests, change in color and fading can be prevented.
Tegaserod is an agonist of serotonin type-4 (5-HT4) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract. 

Based on in vitro binding affinity and functional assessment, at clinically relevant plasma concentrations, tegaserod is an antagonist at 5-HT2B receptors in humans. It is expected to have minimal binding to 5-HT1 receptors. Tegaserod has no affinity for 5-HT3 or dopamine receptors. 

The main metabolite, M29, has negligible affinity for 5-HT4 receptors in vitro.

In vivo studies showed that tegaserod enhanced basal motor activity and normalized impaired motility throughout the gastrointestinal tract. In addition, studies demonstrated that tegaserod moderated visceral sensitivity during colorectal distension in animals.
Purpose: The purpose of the research is to learn more about how the lining of arteries in the body (called the endothelium) and insulin work in adolescents. Abnormalities in how the blood vessels and insulin work in adolescents may cause high blood pressure, type 2 diabetes, stroke and heart disease.

Healthy adolescents between 8 and 18 years of age are being studied in the Ohio State University General Clinical Research Center. Two visits will be necessary. One will be a screening visit to determine the child's stage of puberty and obtain a medical history. The second will be the study visit. During the latter, blood vessel function will be determined by studying the change in forearm blood flow before and after blood flow to the forearm is stopped. Insulin sensitivity will be determined using glucose water given into a vein.
Compounds modulating CD59 mediated complement activity, compositions including these compounds, and methods of making and using the compounds are disclosed, which are based on the identification of the hu CD59 amino acid residues which serve as the binding site for CD59-C9 interactions. These residues correspond to amino acid residues 42–58, and bind to the region of C9 corresponding to human 334–418, more specifically, between amino acid residues 359 and 384. Compounds can be derived using this basic amino acid sequence and corresponding three dimensional structure within the protein using any of several techniques known to those skilled in the art, including rational drug design using computer data bases and modeling of peptide/protein-ligand binding, antibodies and anti-idiotypic antibodies generated to the proteins or peptides containing this peptide sequence, and modified peptides. Those compounds imitating the structure and/or function of the peptide region are referred to herein as “peptidomimetics”, and include small molecules which present the surface exposed side chains in these amino acids in the same relative positions, compounds identified by combinatorial chemistry techniques which bind to the active portions of human C9, as well as modified peptides. The compounds can be used to inhibit complement by binding to C9 analogously to CD59, or to maintain complement inhibition, by blocking CD59 binding to C9. The compounds can be administered locally or systemically in any suitable carrier in an amount effective to either inhibit complement or block the inhibition of complement, in a patient in need of treatment thereof.
PURPOSE:To cause extract to be adsorbed uniformly on powder or granular material at high efficiencies without damaging the quality of extract or powder and granular material by filling material to be extracted and powder or granular material separately into a pressure vessel so as to be brought into contact with extraction solvents formed into a supercritical or liquid state. CONSTITUTION:Pretreated black pepper is filled into an extraction tank 1, while granules of aspartame(AP) are filled into an adsorption tank 2. Liquid carbon dioxide from a bomb 3 is pressurized to a set pressure by means of a pump 4 and then heated by means of a heater 5 so as to be formed into a supercritical or liquid state, whereby the carbon dioxide is led to the extraction tank 1, where piperine in black pepper is selectively extracted. The carbon dioxide into which piperine has been dissolved at a high concentration is led to the adsorption tank 2 and penetrates into granules of AP. Piperine is adsorbed into the AP granules, so that aftertaste improving effect is obtained. Consequently, since extraction, separation, and addition can be achieved in one step operation, processes can be greatly simplified, and further, tint, properties, etc., of AP are not adversely affected, enabling also delicate adjustment of addition quantities.
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS).

The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.

Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase.
The invention discloses a composition with functions of whitening and brightening skin color and a preparation method and application thereof, wherein the composition comprises the following components: olive oil, linseed oil, ultrapure curcumin, almond oil, VCIP. The composition comprises the following components in parts by weight: 18-20 parts of olive oil, 14-16 parts of linseed oil, 0.4-0.8 part of ultrapure curcumin, 14-16 parts of almond oil and 78-55 parts of VCIP 45. The composition comprises the following components in percentage by mass: 19.5% of olive oil, 15% of linseed oil, 0.5% of ultrapure curcumin, 15% of almond oil and 50% of VCIP. The invention also provides a preparation method and application of the composition. The composition can be used for preparing skin care products. The skin care product comprises skin care oil. The composition prepared by the invention is suitable for skin darkness and melanin precipitation caused by various reasons, and can whiten and whiten the skin and keep the skin moist and healthy while improving and brightening the skin color.
Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.